<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211207053323N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-19</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of injection of Mitomycin c and Bevacizumab on intraocular pressure after Ahmed Glaucoma Valve (AGV) implantation surgery</public_title>
      <acronym></acronym>
      <scientific_title>The effect of injection combination of Mitomycin c and Bevacizumab on outcome of intraocular pressure after Ahmed Glaucoma Valve (AGV) implantation surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-16</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60675</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Limited Randomization Method We will use block randomization
The randomization tool is also used from sequence generation software, which is Random allocation software, random sequence generation software, in addition to simple randomization, is capable of generating random sequence by block method.
In order to conceal, we use allocation concealment, which refers to the method used to perform a random sequence on the study participants, so that the allocated group is not known before the allocation of the individual.
By using opaque letter envelopes sealed with a random sequence (Sequentially numbered, sealed, opaque envelopes), in this method, each of the random sequences created is recorded on a card, and the cards are placed inside the letter envelopes in order They are placed. In order to maintain a random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lid of the letter envelopes is glued and placed in a box. At the time of starting the registration of participants, based on the order in which eligible participants entered the study, one of the envelopes will be opened and the assigned group of that participant will be revealed, Blinding description: The method of blinding or covering a single blind is followed. In this method, the trial is planned in such a way that the participant does not know which of the two control or test groups she belongs to.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Neovascular glaucoma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: to insert the AGV (scleral patch graft, scleral tunnel), the conjunctiva is cut 4 mm away from the limbus in the upper outer quadrant. 20 mg of triamcinolone is injected under the tendon around it and fixed to the sclera with 2 sutures with 0-0 silk thread. The AGV tube enters the anterior chamber from 2 mm of the limbus, so that 1-2 mm of it is inside the anterior chamber.The tube is then sutured to the sclera with 0-10 nylon thread. In the SPG method, the donor sclera is placed approximately 7 x 4 mm on the exposed part of the tube and then it is attached to the sclera with 0-10 nylon. Create a small tunnel with a 23 gauge needle, through which the tube enters the anterior chamber and the two sides of the flap are sealed with nylon 0-10.Finally, the conjunctiva and tendon are sutured continuously with 10‐10 and vicryl thread. Mitomycin is placed in the form of a sponge with a concentration of 0.04% for 2 minutes under the conjunctiva. 0.025ml is injected intrachemically with a 23-gauge needle head. Intervention 2: Control group: to insert the AGV (scleral patch graft, scleral tunnel), the conjunctiva is cut 4 mm away from the limbus in the upper outer quadrant. 20 mg of triamcinolone is injected under the tendon around it and fixed to the sclera with 2 sutures with 0-0 silk thread. The AGV tube enters the anterior chamber from 2 mm of the limbus, so that 1-2 mm of it is inside the anterior chamber.The tube is then sutured to the sclera with 0-10 nylon thread. In the SPG method, the donor sclera is placed approximately 7 x 4 mm on the exposed part of the tube and then it is attached to the sclera with 0-10 nylon. Create a small tunnel with a 23 gauge needle, through which the tube enters the anterior chamber and the two sides of the flap are sealed with nylon 0-10.Finally, the conjunctiva and tendon are sutured continuously with 10‐10 and vicryl thread.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Emad Soleimani Bayatiani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital,  24 meters Street, Ophtalmology department</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6155844419</zip>
        <telephone>+98 21 2245 4292</telephone>
        <email>emadf14@yahoo.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Emad Soleimani Bayatiani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital, 24 meters Street, Ophtalmology department</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6155844419</zip>
        <telephone>+98 21 2245 4292</telephone>
        <email>emadf14@yahoo.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient with uncontroll glaucoma and indicated for shunt</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age below 18 years
Neovascular glaucoma secondary to tumor or uveitis
Follow up less than 6 months
Previous shunt devices
Simultaneous intravitreal injection of bevacizumab (IVB)
Non-diabetic people with a history of failed trabeculectomy surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H40.10X0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified open-angle glaucoma, stage unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: to insert the AGV (scleral patch graft, scleral tunnel), the conjunctiva is cut 4 mm away from the limbus in the upper outer quadrant. 20 mg of triamcinolone is injected under the tendon around it and fixed to the sclera with 2 sutures with 0-0 silk thread. The AGV tube enters the anterior chamber from 2 mm of the limbus, so that 1-2 mm of it is inside the anterior chamber.The tube is then sutured to the sclera with 0-10 nylon thread. In the SPG method, the donor sclera is placed approximately 7 x 4 mm on the exposed part of the tube and then it is attached to the sclera with 0-10 nylon. Create a small tunnel with a 23 gauge needle, through which the tube enters the anterior chamber and the two sides of the flap are sealed with nylon 0-10.Finally, the conjunctiva and tendon are sutured continuously with 10‐10 and vicryl thread. Mitomycin is placed in the form of a sponge with a concentration of 0.04% for 2 minutes under the conjunctiva. 0.025ml is injected intrachemically with a 23-gauge needle head.</i_keyword>
      <i_keyword>Control group: to insert the AGV (scleral patch graft, scleral tunnel), the conjunctiva is cut 4 mm away from the limbus in the upper outer quadrant. 20 mg of triamcinolone is injected under the tendon around it and fixed to the sclera with 2 sutures with 0-0 silk thread. The AGV tube enters the anterior chamber from 2 mm of the limbus, so that 1-2 mm of it is inside the anterior chamber.The tube is then sutured to the sclera with 0-10 nylon thread. In the SPG method, the donor sclera is placed approximately 7 x 4 mm on the exposed part of the tube and then it is attached to the sclera with 0-10 nylon. Create a small tunnel with a 23 gauge needle, through which the tube enters the anterior chamber and the two sides of the flap are sealed with nylon 0-10.Finally, the conjunctiva and tendon are sutured continuously with 10‐10 and vicryl thread.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intraocular pressure reduction percentage after surgery. Timepoint: One week, four weeks, six weeks, eight weeks, three months and 6 months are followed. Method of measurement: Applanation tonometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-08-06</approval_date>
        <contact_name>Ethics Committee of Ahwaz University of Medical Sciences</contact_name>
        <contact_address>Ethics Committee of Ahwaz University of Medical Sciences Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
